Immunological effects of BRAF plus MEK inhibition
Immunological effects of BRAF plus MEK inhibition
复制标题
DOI：
10.1080/2162402x.2018.1468955
复制
发表时间：
2018-01-01
期刊：
影响因子：
7.2
通讯作者：
Dummer, Reinhard
中科院分区：
文献类型：
--
作者：
Ascierto, Paolo A.;Dummer, Reinhard
免疫治疗的最新进展延长了转移性黑色素瘤的总体生存时间，并有可能达到长期受益。基于BRAF和MEK抑制的靶向治疗似乎也有长期的有益效果，这在基线特征良好的患者中更为明显，即乳酸脱氢酶水平正常，无脑转移，肿瘤负担低。靶向治疗的长期益处可能与免疫调节有关：事实上，BRAF和MEK抑制剂会影响肿瘤微环境和免疫监测，而且已有研究表明，对靶向治疗完全有效的患者已有良好的免疫学特征。
Recent developments in immunotherapy have prolonged overall survival in metastatic melanoma with the possibility to reach a long-term benefit. Targeted therapies based on BRAF and MEK inhibition also seem to have a long-term beneficial effect, which is more evident in patients with favorable baseline characteristics, namely normal levels of lactate dehydrogenase, without brain metastases, and low tumor burden. This long-term benefit of targeted therapies might be related to an immune-modulation: indeed BRAF and MEK inhibitors affect tumor microenvironment and immune surveillance, and it has been shown that patients with complete response to targeted treatment have a pre-existing favorable immunologic signature.